Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide

American Journal of Hematology

Volumn 88, Issue 8, 2013, Pages 719-719

  Sanchorawala, Vaishali ^a   Shelton, Anthony C ^a   Zeldis, Jerome B ^b   Seldin, David C ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; MELPHALAN;

AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGISTRY; CANCER RISK; DRUG MEGADOSE; HUMAN; LETTER; LUNG CANCER; METASTASIS; MULTIPLE CYCLE TREATMENT; MYELOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SECOND CANCER; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANGIOGENESIS INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; THALIDOMIDE;

EID: 84880836315     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23470     Document Type: Letter

References (10)

1. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40, 576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-1365.
2. Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995;1:33-42.
3. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006;15:2020-2026.
4. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-1769.
5. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-1781.
6. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782-1791.
7. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119:2764-2767.
8. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-470.
9. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492-496.
10. Altekruse SF, Kosary CL, Krapcho M, et al. editors. SEER Cancer Statistics Review, 1975-2007. National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2007/. Based on November 2009 SEER data submission, posted to the SEER website, 2010. Last Accessed on March 5, 2013.